Ukraine receives first batch of COVID antiviral medicine Molnupiravir

Ukraine receives first batch of COVID antiviral medicine Molnupiravir

Ukraine has received the first batch of 60,000 courses of Molnupiravir for the treatment of COVID-19, Minister of Health Viktor Liashko wrote on Facebook.

"Today [February 6], 60,000 courses of Molnupiravir, intended for the treatment of COVID-19, arrived in Ukraine. The drug manufacturer is the American pharmaceutical company Merck Sharp & Dohme," he wrote.

According to the minister, Ukraine began work on contracting Molnupiravir in November 2021 to get ready for the next wave of COVID-19. The Ministry of Health will distribute medicines and send them to the regions. By April 2022, Ukraine will receive another 240,000 courses of the drug.

Molnupiravir belongs to a class of antivirals that block an enzyme needed by the virus to reproduce the genetic code, preventing the virus from multiplying and reducing the risk of severe disease. The drug is available in a pill form, has no special storage requirements and is convenient to take. It has been registered and approved for emergency use in the United States, Japan, the United Kingdom and other countries.


Let’s get started read our news at facebook messenger > > > Click here for subscribe

While citing and using any materials on the Internet, links to the website not lower than the first paragraph are mandatory. In addition, citing the translated materials of foreign media outlets is possible only if there is a link to the website and to the website of a foreign media outlet. Citing and using materials in offline media, mobile apps, Smart TV are allowed only with written permission from Ukrinform. News and publications marked as "Advertisement" and "PR" and articles in the section "Releases" include promoted content, and an advertiser is responsible for the content.

© 2015-2022 Ukrinform. All rights reserved.

Website design Studio Laconica

Extended searchHide extended search
By period: